Dydrogestrion use in which condition
Reading File
Finding Sources
Searching PubMed
dydrogesterone indications clinical use
Reading File
Searching PubMed
dydrogesterone threatened miscarriage pregnancy
Reading File
Finding Sources
Finding Sources
Searching the Web
dydrogesterone clinical indications uses gynaecology
Here is a complete, organized answer on dydrogesterone's clinical uses:
Dydrogesterone (Duphaston) - Clinical Indications
Dydrogesterone is a synthetic progestogen that closely resembles natural progesterone in structure and action. It is orally active, does not suppress ovulation at therapeutic doses, and has no androgenic, estrogenic, or glucocorticoid effects. It is used across a wide range of conditions linked to progesterone insufficiency.
Obstetric Indications
| Condition | Details |
|---|---|
| Threatened abortion | Most common use. Given 10 mg twice or three times daily to support early pregnancy. A 2025 network meta-analysis (PMID 39698935) confirmed efficacy vs. other progestogens in first threatened miscarriage. |
| Recurrent pregnancy loss (habitual abortion) | Second most common indication; given from early pregnancy to reduce risk of further loss. |
| Luteal phase insufficiency | Supports the luteal phase to maintain the endometrium for implantation. |
| Luteal phase support in ART (IVF/IUI) | Used post egg retrieval to support the endometrium. |
Gynecological Indications
| Condition | Dose / Regimen |
|---|---|
| Dysmenorrhea | 10 mg twice daily on days 5-25 of cycle |
| Endometriosis | 20-30 mg/day, either continuously or on days 5-21; reduces pelvic pain significantly (60 mg in luteal phase also shown effective) - Berek & Novak's Gynecology |
| Premenstrual syndrome (PMS) | 10 mg twice daily on days 14-25 |
| Irregular menstrual cycles | 10 mg twice daily on days 11-25 |
| Secondary amenorrhea | Combined with an estrogen to induce withdrawal bleeding |
| Dysfunctional uterine bleeding (DUB) | 10 mg twice daily on days 11-25, with estrogen |
| Infertility due to luteal phase defect | 10 mg twice daily on days 14-25 |
Hormone Replacement Therapy (HRT)
- Used as the progestogen component in combined estrogen-progestogen HRT, both in sequential (perimenopausal) and continuous combined (postmenopausal) regimens.
- Example product: Estradiol 1 mg/2 mg + Dydrogesterone 10 mg tablets (e.g., Femoston).
Key Properties That Make It Preferred
- Orally bioavailable - unlike natural progesterone, which undergoes heavy first-pass metabolism
- No androgenic, estrogenic, or glucocorticoid effects - cleaner side-effect profile
- Does not suppress ovulation - suitable for use in women trying to conceive
- Extensive safety data in pregnancy - over 10 million pregnancies exposed without confirmed teratogenic signal (though very rare reports of hypospadias with some progestogens exist as a class concern)
Summary Table of All Indications
| Category | Conditions |
|---|---|
| Obstetric | Threatened abortion, recurrent miscarriage, luteal phase support, ART support |
| Menstrual disorders | Dysmenorrhea, irregular cycles, secondary amenorrhea, DUB |
| Gynecological | Endometriosis, PMS, infertility (luteal phase defect) |
| Menopausal | HRT (combined with estrogen) |
Sources: Berek & Novak's Gynecology; real-world Indian cohort study (PMC11075425); Summary of Product Characteristics
This is a shared conversation. Sign in to Orris to start your own chat.